Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs
April 24, 2017 07:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, April 24, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") announced that effective today, Dr. Steven James will join the Company as Vice President...
Insys Therapeutics Reports Fourth Quarter and Year End 2016 Results
April 03, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, April 03, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced financial results for the three- and twelve-month periods ended December...
Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017
March 27, 2017 07:00 ET
|
Insys Therapeutics, Inc.
PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the...
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug
March 23, 2017 07:33 ET
|
Insys Therapeutics, Inc.
PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final...
Insys Therapeutics Announces Delay in the Release of its Fourth Quarter and Full Year 2016 Results
March 15, 2017 16:30 ET
|
Insys Therapeutics, Inc.
PHOENIX, March 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “the Company”) today announced that the Company will delay the release of its financial results for the...
Insys Therapeutics to Report Fourth Quarter and Full Year 2016 Results
March 02, 2017 09:18 ET
|
Insys Therapeutics, Inc.
PHOENIX, March 02, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) (“Insys” or “Company”) today announced that the Company will release its financial results for the fourth quarter...
Insys Therapeutics Announces Use of Cannabidiol Oral Solution for Compassionate Use Studies in Patients Completing Long-Term Safety Study
February 15, 2017 07:00 ET
|
Insys Therapeutics, Inc.
CHANDLER, Ariz., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that the Company is providing for the use of Cannabidiol Oral...
Insys Therapeutics, Inc. to Present at 2017 RBC Capital Markets Global Healthcare Conference
February 14, 2017 16:30 ET
|
Insys Therapeutics, Inc.
PHOENIX, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Interim Chief Executive Officer, and...
Insys Therapeutics Announces Retirement of Dr. John N. Kapoor as CEO and Chairman; Appoints Dr. Santosh Vetticaden as Interim CEO and Steven Meyer as Chairman of the Board
January 09, 2017 06:50 ET
|
Insys Therapeutics, Inc.
PHOENIX, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that Dr. John N. Kapoor, its Founder, President and Chief Executive...
Insys Therapeutics, Inc. to Present at J.P. Morgan 35th Annual Healthcare Conference
January 04, 2017 16:30 ET
|
Insys Therapeutics, Inc.
PHOENIX, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (“Insys” or “the Company”) (NASDAQ:INSY) today announced that Santosh Vetticaden, MD, PhD, Senior Vice President and Chief Medical...